University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Arie Perry

Arie Perry, M.D.

Neuropathologist

Dr. Arie Perry, director of Neuropathology at UCSF Medical Center, specializes in brain tumor pathology and genetics. He also maintains an international consult service for challenging cases involving brain tumor diagnosis. His research focuses on biomarker development for enhanced diagnosis, prognostic accuracy and management of brain tumor patients.

Perry received a medical degree and pathology residency training at the University of Texas, Southwestern in Dallas, followed by fellowships in surgical pathology and neuropathology at the Mayo Clinic in Rochester, Minn. He is a member of several professional organizations, including the American Association of Neuropathologists, International Society of Neuropathology, U.S. and Canadian Association of Pathology and the Society for Neuro-Oncology. He is the recipient of numerous teaching awards and has authored various publications, including the textbook, "Practical Surgical Neuropathology." He is a professor of pathology and neurosurgery at UCSF and director of the Neuropathology Fellowship Training Program.

Conditions & Treatments

More about Arie Perry

Education

University of Texas Southwestern Medical School 1990

Residencies

University of Texas Hospital, Dallas, Pathology 1994

Fellowships

Mayo Clinic, Rochester, Minn., Surgical Pathology, Neuropathology 1998

Selected Research and Publications

  1. Pekmezci M, Perry A. Neuropathology of brain metastases. Surg Neurol Int. 2013; 4(Suppl 4):S245-55.
  2. Yeo YH, Byrne NP, Counelis GJ, Perry A. Adult with cerebellar anaplastic pilocytic astrocytoma associated with BRAF V600E mutation and p16 loss. Clin Neuropathol. 2013 May-Jun; 32(3):159-64.
  3. Hiniker A, Hagenkord JM, Powers MP, Aghi MK, Prados MD, Perry A. Gliosarcoma arising from an oligodendroglioma (oligosarcoma). Clin Neuropathol. 2013 May-Jun; 32(3):165-70.
  4. Venneti S, Felicella MM, Coyne T, Phillips JJ, Gorovets D, Huse JT, Kofler J, Lu C, Tihan T, Sullivan LM, Santi M, Judkins AR, Perry A, Thompson CB. Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas. J Neuropathol Exp Neurol. 2013 Apr; 72(4):298-306.
  5. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK. Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance. Clin Cancer Res. 2013 Apr 1; 19(7):1773-83.
  6. Poole Perry LJ, Jakobiec FA, Zakka FR, Reichel E, Herwig MC, Perry A, Brat DJ, Grossniklaus HE. Reactive Retinal Astrocytic Tumors (So-called Vasoproliferative Tumors): Histopathologic, Immunohistochemical, and Genetic Studies of Four Cases. Am J Ophthalmol. 2013 Mar; 155(3):593-608.e1.
  7. Korshunov A, Ryzhova M, Jones DT, Northcott PA, van Sluis P, Volckmann R, Koster J, Versteeg R, Cowdrey C, Perry A, Picard D, Rosenblum M, Giangaspero F, Aronica E, Schüller U, Hasselblatt M, Collins VP, von Deimling A, Lichter P, Huang A, Pfister SM, Kool M. LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol. 2012 Dec; 124(6):875-81.
  8. Aref D, Moffatt CJ, Agnihotri S, Ramaswamy V, Dubuc AM, Northcott PA, Taylor MD, Perry A, Olson JM, Eberhart CG, Croul SE. Canonical TGF-ß Pathway Activity Is a Predictor of SHH-Driven Medulloblastoma Survival and Delineates Putative Precursors in Cerebellar Development. Brain Pathol. 2013 Mar; 23(2):178-91.
  9. Joseph NM, Phillips J, Dahiya S, M Felicella M, Tihan T, Brat DJ, Perry A. Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants. Mod Pathol. 2013 Mar; 26(3):315-26.
  10. Ellezam B, Theeler BJ, Walbert T, Mammoser AG, Horbinski C, Kleinschmidt-DeMasters BK, Perry A, Puduvalli V, Fuller GN, Bruner JM, Aldape KD. Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas. Acta Neuropathol. 2012 Sep; 124(3):449-51.
  11. Felicella MM, Hagenkord JM, Kash SF, Powers MP, Berger MS, Perry A. A common 8q (MYC) amplification detected in a multifocal anaplastic astrocytoma by SNP array karyotyping. Clin Neuropathol. 2012 Jul-Aug; 31(4):210-5.
  12. Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell. 2012 May 15; 21(5):601-13.
  13. Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, Perry A, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch DH. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A. 2012 May 29; 109(22):8710-5.
  14. Rodriguez FJ, Folpe AL, Giannini C, Perry A. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012 Mar; 123(3):295-319.
  15. Goldhoff P, Clarke J, Smirnov I, Berger MS, Prados MD, James CD, Perry A, Phillips JJ. Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtype. J Neuropathol Exp Neurol. 2012 Jan; 71(1):83-9.
  16. Barajas RF, Perry A, Sughrue M, Aghi M, Cha S. Intracranial subdural osteoma: A rare benign tumor that can be differentiated from other calcified intracranial lesions utilizing MR imaging. J Neuroradiol. 2012 Oct; 39(4):263-6.
  17. Han SJ, Clark AJ, Ivan ME, Parsa AT, Perry A. Pathology of pineal parenchymal tumors. Neurosurg Clin N Am. 2011 Jul; 22(3):335-40, vii.
  18. Remke M, Hielscher T, Northcott PA, Witt H, Ryzhova M, Wittmann A, Benner A, von Deimling A, Scheurlen W, Perry A, Croul S, Kulozik AE, Lichter P, Taylor MD, Pfister SM, Korshunov A. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 2011 Jul 1; 29(19):2717-23.
  19. Yu J, Deshmukh H, Payton JE, Dunham C, Scheithauer BW, Tihan T, Prayson RA, Guha A, Bridge JA, Ferner RE, Lindberg GM, Gutmann RJ, Emnett RJ, Salavaggione L, Gutmann DH, Nagarajan R, Watson MA, Perry A. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res. 2011 Apr 1; 17(7):1924-34.
  20. Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011 Mar; 121(3):381-96.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2013 The Regents of The University of California